RNA-Triggered Chromatin Shredding Hits Cancer's Hardest Targets.

RNA-triggered chromatin shredding using Cas12a2 can selectively eliminate tumor cells with mutations in TP53, MYC, and other difficult-to-drug cancer genes in mouse models.

• Why it matters: This approach addresses the challenge of targeting cancers driven by mutations that have resisted conventional therapies, potentially offering a new treatment strategy for hard-to-treat tumors.
• What they did: Researchers activated Cas12a2 by a target transcript in mouse models, demonstrating its ability to specifically eliminate tumor cells harboring mutations in key cancer genes.
• The result: The findings suggest that RNA-triggered chromatin shredding may provide a novel method to target resistant cancer mutations, paving the way for new therapeutic options.